What is Cellares?
Cellares operates as an Integrated Development and Manufacturing Organization (IDMO) dedicated to the automated, large-scale production of cell therapies. The company's core innovation lies in its proprietary automated manufacturing and quality control platforms, the Cell Shuttle and Cell Q. These systems are designed to provide end-to-end cell therapy manufacturing and automated testing, enabling higher process reproducibility, improved manufacturing success rates, and significantly higher throughput compared to conventional methods. By offering cGMP-compliant solutions, Cellares aims to overcome the limitations of labor-intensive production models, positioning itself as a key enabler for global biopharmaceutical partners seeking to scale their cell therapy pipelines.
How much funding has Cellares raised?
Cellares has raised a total of $612M across 4 funding rounds:
Series A
$18M
Series B
$82M
Series C
$255M
Series D
$257M
Series A (2020): $18M with participation from Eclipse Ventures
Series B (2021): $82M led by 8VC, Eclipse, Skyviews Life Science, and Decheng Capital
Series C (2023): $255M supported by 8VC, KOCH Technology, and Bristol-Myers Squibb
Series D (2026): $257M featuring T. Rowe Price, Intuitive Growth Ventures, Eclipse Capital Management, BlackRock, and Gates Frontier
Key Investors in Cellares
Eclipse Ventures
Eclipse Ventures is a venture capital firm that invests in companies developing advanced technologies and innovative manufacturing solutions. Their focus on hardware and deep technology aligns with Cellares' mission to automate complex biological manufacturing processes.
T. Rowe Price
T. Rowe Price is a global investment management firm that provides a wide range of investment products and services. Their participation suggests a belief in Cellares' long-term growth potential and its impact on the broader healthcare and biotechnology markets.
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines. Their investment in Cellares indicates a strategic interest in securing advanced manufacturing capabilities for future cell therapy products and a validation of Cellares' technology within the pharmaceutical industry.
What's next for Cellares?
The substantial enterprise-level funding and recent strategic investment signal a strong market validation for Cellares' innovative approach to cell therapy manufacturing. This capital infusion is expected to accelerate the expansion of its IDMO Smart Factory network, particularly in Europe and Japan, and further enhance its automated manufacturing and quality control platforms. Cellares is poised to play a critical role in enabling the commercialization of a new generation of cell therapies by providing scalable, reproducible, and cost-effective manufacturing solutions. The company's focus on addressing the critical bottlenecks in cell therapy production positions it for significant growth as the demand for these advanced therapies continues to rise.
See full Cellares company page
